After years of research and development, the field of bispecific antibodies (BsAbs) is gaining momentum. More than a dozen bispecific antibodies have secured FDA approval. These new therapies have added much-needed therapeutic value to challenging disease states such as relapsed/refractory multiple myeloma. In 12 months, three distinct CD3-engaging...
read more